X

Features/News

“Gaining Patients’ Trust in the Age of COVID-19” Recap

July 29th, 2020- Over 250 community providers, educators, and partners joined us for the webinar, “Gaining Patients’ Trust in the Age of COVID-19” on Wednesday, July 29th, 2020 from 11AM-12:30PM. With the ultimate aim of discussing the challenges of and […]

FDA Approves New HIV Treatment for Patients With Limited Treatment Options

This article originally appeared on fda.gov. To see the full article, click here. July 2nd, 2020- Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried […]

Risk, Resilience and Thriving among Racial/Ethnic Minorities and Undeserved Populations at-risk for Substance Use Disorders

This Special Issue of The American Journal on Drug and Alcohol Abuse (Impact Factor = 2.9) will include a mix of of original research reports, brief reports, systematic reviews , narrative reviews or qualitative research from drug and alcohol abuse […]

Op-ed: As COVID-19 flares behind bars, now’s not the time for more Terre Haute executions

The following Op-Ed was written by Dr. Nina Harawa, CHIPTS Policy Impact Core Director.  The full article published on indystar.com is available here.  Nina T. Harawa July 8, 2020 6:00 AM As America labors under the effects of a global […]

New Reports from CHIPTS Ending the HIV Epidemic Supplement Projects

July 9th, 2020- CHIPTS is excited to share preliminary reports from our three Ending the HIV Epidemic (EHE) supplement projects. These one-year, formative projects were funded by the National Institute of Mental Health to enhance the implementation science knowledge base […]

Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

This article originally appeared on niaid.nih.org. To see the full article, click here. July 7th, 2020- A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than […]

HPTN 083 Study Demonstrates Superiority of Cabotegravir for the Prevention of HIV

This article originally appeared on hptn.org. To see the full article, click here. DURHAM, N.C. – Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender […]

CHIPTS AIDS 2020 Conference Scholarship

Application Deadline: Tuesday, June 30, 2020 The Center for HIV Identification, Prevention and Treatment Services is pleased to announce scholarships for individuals who would like to attend the 23rd International AIDS virtual conference from July 6-10, 2020. The scholarship aims […]

Spotlight: Jesse Clark

Jesse Clark, MD, MSc, is an Associate Professor-in-Residence in the Department of Medicine, Division of Infectious Diseases, and Department of Family Medicine. A member of the CHIPTS Combination Prevention Core, his research focuses on questions of HIV prevention and STI […]

A Community’s Guide to Self-Care During a Pandemic

April 24th, 2020- As we continue to take care of ourselves amidst the stress of the coronavirus pandemic, gauging and understanding our individual needs could not be more important. To help with these efforts, the COVID-19 Racism Equity Task-force at […]

X